We have investigated proteinases that degrade cartilage collagen. We show that pro-inflammatory cytokines act synergistically with oncastatin M to promote cartilage collagen resorption by the up-regulation and activation of matrix metalloproteinases (MMPs). The precise mechanisms are not known, but involve the up-regulation of c-fos, which binds to MMP promoters at a proximal activator protein-1 (AP-1) site. This markedly up-regulates transcription and leads to higher levels of active MMP proteins.
Cartilage composition and breakdown
Cartilage is composed of a unique mixture of collagens, proteoglycans and glycoproteins that are precisely assembled and maintained by chondrocytes [1, 2] . The collagen fibres give strength and rigidity to the tissue, while the proteoglycans, trapped within this network, swell as they hydrate. This allows the tissue to provide easy movement under load, to distribute load and to retain shape after compression [3] .
In joint cartilage, tissue is broken down after cytokines and other stimuli act on chondrocytes and synovial cells to up-regulate and activate proteinases [4] . In healthy tissue these enzymes maintain the balance between synthesis and degradation of the extracellular matrix of cartilage within the joint. Their inappropriate up-regulation and subsequent activation in disease leads to joint destruction and the loss of joint function. Our aim has been to discover the key cytokines, cells and enzymes in this process, in order to develop new therapies that can prevent joint destruction.
Collagen, a key component of cartilage
Proteoglycan and glycoproteins can be degraded rapidly, but the chondrocytes within the cartilage can resynthesize these molecules within a short space of time [5] . In contrast, collagen is often released more slowly; however, once the fibrillar structure is lost then it is difficult for the tissue to recover, and irreversible tissue destruction is often the result [6] . We have therefore focused our attention on the endopeptidases that cleave fibrillar collagen.
Endopeptidases are classified by the chemical group at the active site responsible for peptide bond cleavage [7] . In general, cysteine and aspartate proteinases act intracellularly at low pH, whereas serine and metalloproteinases act extracellularly at neutral pH. Both intracellular and extracellular routes are involved in turnover of the extracellular matrix [8] .
The matrix metalloproteinases (MMPs) together cleave all extracellular matrix components, and have important roles to play in the body under normal physiological conditions, e.g. in growth and development [9] . However, in pathological states such as cancer, periodontal disease, rheumatoid arthritis (RA) and osteoarthritis (OA), MMPs are overproduced and/or inadequately inhibited. Although collagen fibres are relatively resistant to proteolytic cleavage, the MMPs are proposed to be the principle enzyme group responsible for collagen turnover [10] .
Proteinases that break down collagen
The first vertebrate collagenase was described in 1962 by Gross and Lapierre [11] , and was shown to specifically cleave the triple-helical collagen molecule at a single point across all three chains, three-quarters of the way along the molecule from the N-terminus. This collagenase was the first described member of the MMP family, and other members, namely MMP-2, MMP-8, MMP-13 and MMP-14, also cleave collagen in this specific fashion [12] [13] [14] [15] [16] . All MMPs are synthesized in a proenzyme form that requires activation, and other MMPs (e.g. MMP-3) can activate the collagenases. Some MMPs (e.g. the membrane-type MMPs; stromelysin 3) have a furin recognition site that allows intracellular activation, such that these enzymes can be secreted in an active form [17] . They can then initiate the activation of other MMPs at the cell surface. MMPs can also be activated by serine proteinases, such as plasmin generated from plasminogen by plasminogen activators. Inhibition of furin or plasminogen activators can block cartilage collagen destruction [18] . All MMPs are inhibited by a family of proteins called the tissue inhibitors of metalloproteinases (TIMPs-1-4), which bind active MMPs stoichiometrically to block substrate digestion [4] .
Early work on MMP-1
My (T.E.C.) early work involved the purification of pig collagenase [19] , and subsequent studies established the full-length structure of the recombinant pig enzyme [20] . This showed that the N-terminal catalytic domain is ellipsoidal, with an active-site cleft which contains the catalytic zinc ion at the bottom. This is attached, via a flexible hinge region, to a C-terminal domain that has a unique four-bladed ␤-propellor structure. In spite of these advances, the structure gives little clue as to the mechanism of action of this collagenase. It is known that the C-terminal domain is essential for binding to collagen [21] , and different mechanisms have been put forward to explain the cleavage of collagen. The structure of the active-site cleft shows clearly that it is too narrow for the full triple helix to enter. It is proposed that perturbation of the structure occurs at the cleavage site, caused by binding of the C-terminal domain to the triple helix; this exposes one chain to the active-site cleft [22] .
Evidence for involvement of collagenases in joint diseases
There is strong evidence that these enzymes are involved in the destruction of cartilage collagen within the diseased joint. Many studies show that collagenases are found in synovial fluid [23] , synovial tissue [24] and cartilage tissue [25] . Specific epitopes, only produced after cleavage of collagen by the collagenases, are found within cartilage tissue in disease, and co-localization of MMP and cleavage product has been shown [26] . In animal models, joint destruction is associated with increased levels of the collagenases, and in vitro addition of TIMP-1 to resorbing cartilage blocks the release of collagen. Recent work has investigated the interaction between synovial and cartilage tissue within the joint. In RA in particular, the proliferation of synovial cells and the invasive nature of their penetration into cartilage determines the extent of cartilage and bone destruction. Studies using invasive synovial cells from RA patients implanted into the SCID (severe combined immunodeficiency) mouse model have identified new associations between MMP production and this invasive behaviour [27] . In addition, considerable interest in large multinucleated cells within this synovium have indicated that cathepsin K may also be involved in joint destruction, particularly with regard to bone [28] . RA is thus synovial-driven destruction, whereas in OA the cartilage destruction is chondrocyte-driven. Different therapies are likely to target different parts of the enzyme cascades involved in tissue destruction in these two diseases of the joint.
Cytokines act together in the joint
A variety of cytokines and growth factors are found within the inflamed joint [29] . These include the pro-inflammatory cytokines interleukin-1 (IL-1) and tumour necrosis factor ␣ (TNF␣), both of which are known to initiate the release of proteoglycan, and sometimes collagen, from cartilage [30] . In addition, it is known that a variety of growth factors, such as transforming growth Cytokine synergy, collagenases and cartilage collagen breakdown 127
factor ␤, can protect cartilage from the effects of these pro-inflammatory cytokines [31] . Within the inflamed joint there are a number of cytokines present, and part of our work has involved investigation of the effects of such mixtures of cytokines on cartilage collagen proteolysis. We have found that both IL-1 and TNF␣ can synergize with a member of the IL-6 family of cytokines, oncostatin M (OSM), to promote cartilage collagen destruction [32] .
Collagen release is associated with a large increase (Ͼ20-fold) in collagenolytic activity, a significant proportion of which is in the active form. the level of MMP-1 mRNA produced when IL-1 and OSM are combined is more than 200 times the control level (Figure 1) . OSM is produced within the joint by synovial macrophages, and overexpression of OSM within murine joints causes profound cellular infiltration into the synovium, with subsequent damage to the cartilage and bone within the joint [34] . OSM acts via a specific ␤ receptor [35] which we have found to be expressed by chondrocytes [36] , and treatment of mice with collagen-induced arthritis with an antibody to OSM leads to a marked reduction in disease activity [37] . OSM can also synergize in a similar way with the T cell cytokine IL-17 [38] . Initially it was thought that OSM was unique within the IL-6 family in being able to synergize in this way with IL-1 and TNF␣. However, subsequent studies have shown that both IL-6 and IL-11 can also synergize if they are present along with their respective soluble receptors.
Recent work using adenoviral vectors to deliver both OSM and IL-1 to mouse joints has shown a very marked response by day 7 after injection (A.D. Rowan, W. Hui, C.D. Richards and T.E. Cawston, unpublished work). When both cytokines are present together, then a marked infiltration of cells into the joint is seen, followed by the destruction of cartilage and bone. Proliferating synovial cells penetrate through into the marrow cavity, and marked swelling of treated joints occurs. Immunolocalization studies show that MMP-13 and MMP-3 levels within cartilage are high compared with those in control joints or joints treated with a single cytokine (A.D. Rowan, W. Hui, C.D. Richards and T.E. Cawston, unpublished work).
Mechanism of synergy between IL-1 and OSM
The mechanism of action to explain this synergy is not known. We have shown that the levels of cell surface receptors are not altered after treatment with cytokines, and consider that an overlap of intracellular signalling pathways is responsible. A previous study [40] proposed that there is an OSM response element in the MMP-1 promoter that was responsible for the increased transcription of MMP-1 when astrocytes were treated with combinations of IL-1 and OSM. However, this OSM response element is not operative in chondrocytes or synovial cells. One of the early genes up-regulated by this combination is c-fos, which also responds synergistically to this cytokine combination, and our working hypothesis is that alteration of the Fos/Jun partners at the proximal activator protein-1 (AP-1) site on the MMP-1 promoter dramatically alters transcription of the MMP-1 gene [41] (Figure 2) . We continue to investigate the overlap of signalling pathways, and have used both microarray and proteomic techniques to identify both intracellular and secreted proteins that are up-regulated specifically by this combination of cytokines.
Activation of MMPs -a neglected control point
The transcriptional control of collagenases is complex, and considerable effort has gone into determining mechanisms and pathways. In many situations it is possible to up-regulate collagenolytic MMPs but not see collagen destruction. Human cartilage, if exposed to IL-1 and OSM, up-regulates the levels of MMP-1 to a large extent, but this is not always accompanied by the release of collagen. However, if an activator such as active MMP-3 is added to the cartilage in culture, then early release of collagen is seen. This is illustrated for bovine cartilage in Figure 3 , where release of collagen is seen by day 7 when MMP-3 is added. This demonstrates that the up-regulation of MMP-1 in this system occurs early (by day 2), but no release of collagen is seen until after day 7 because there is no activator of MMP-1 present at the early time points. Similar results are obtained when APMA (aminophenyl mercuric acetate) is added to the culture medium at early time points [42] . These results demonstrate the importance of activation as a control step, and illustrate the potential of blocking collagen turnover by the inhibition of activation cascades.
Synthetic inhibitors of MMPs
Highly specific MMP inhibitors have been made. Initial attempts to produce synthetic MMP inhibitors were based on the collagen cleavage site, with the scissile bond being replaced by a chelating group, such as hydroxamate to co-ordinate the catalytic zinc ion. Carboxylic acid, thiol and phosphorous ligands have been used to bind to zinc in other compounds. These inhibitors initially had problems of oral availability, but now compounds have been designed that can be absorbed by the gut without modification, and this has dramatically improved their oral availability. Non-peptidic inhibitors have also been designed [43] . The solving of crystal structures for MMPs [44] has allowed the fine tuning of inhibitors with increased specificity, and crystal structures have been obtained for the catalytic domains of many MMPs (MMP-1, -2, -3, -7, -8, -9, -11, -13 and -14). At least some of the variation in Transfected cells were split and grown in acid-treated medium for 24 h before being stimulated with IL-1 (1 ng/ml) and/or OSM (10 ng/ml) for another 24 h. Cells were lysed and the luciferase activity was assayed. Plasmid incorparation was determined using Hirt's assay and used to correct for transfection efficiency.
substrate specificity among the MMPs can be explained by differences in the six specificity subsites in the active-site cleft and surrounding sequences. The S1Ј pocket is particularly important, e.g. being deeper in MMP-3 and larger in MMP-8 than in MMP-1. This offers target sites for engineering specificity into synthetic MMP inhibitors. Most early studies involved the treatment of cancer. For example Marimastat (BB-2516), an orally available hydroxamate inhibitor of MMPs with limited ability to inhibit sheddase activity, is in clinical development [45] . The inhibitor BAY 12-9566 targets MMP-3 (with low activity against MMP-1) for the treatment of OA [46] . It also inhibits MMP-2, -8, -9 and -13, and was effective in models of OA [42] . However, BAY 12-9566 was withdrawn from a phase III trial involving 1800 patients with arthritis following negative effects in cancer trials of the same drug [47] .
As irreversible cartilage damage appears to occur only after the collagen network has been destroyed, it is important to ensure that the collagenases are a potential therapeutic target. Trocade (Ro 32-3555) has a low nanomolar K i against MMP-1, -8 and -13, with approx. 10-100-fold lower potency against MMP-2, -3 and -9. It blocks IL-1␣-induced collagen release from cartilage explants and, in vivo, prevented cartilage degradation in a rat granuloma model, a Propionibacterium acnes-induced rat arthritis model and an OA model using the SRT/ORT mouse (a well recognized breed susceptible to OA) [48] . However, large-scale trials of Trocade in patients with RA were terminated, presumably because of a lack of efficacy, and its failure does leave the future of therapies targeted at the collagenases in question. Bovine nasal cartilage discs were cultured in medium with or without active MMP-3, IL-1 and/or OSM. Medium was removed on day 7 and replenished with identical reagents. On day 14, medium was removed and the remaining cartilage was digested with papain. As a measure of collagen, the levels of hydroxyproline in day 7 and day 14 media and in cartilage digests were assayed. Collagen release by day 7 was calculated as a percentage of total collagen. Values are meansϮS.D.; ***PϽ0.001
It will be interesting to see whether the blocking of one enzyme in the MMP family with some inhibition of the others is sufficient to halt the progressive and chronic destruction of connective tissue seen in the arthritides. It may be necessary to combine proteinase inhibitors, either in sequence or with other agents that target other specific steps in the pathogenesis, before the chronic cycle of joint destruction found in these diseases can be broken [49] .
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